Abstract
Introduction
The National Comprehensive Cancer Network (NCCN) developed clinical practice guidelines for germline pathogenic variants in highly penetrant genes, such as TP53 and PTEN, and in moderately penetrant genes, such as CHEK2, ATM and PALB2. Whether the practice of radiographic surveillance of patients with pathogenic variants in genes other than BRCA1/2 complies with current NCCN guidelines remains unclear.
Methods
Retrospective review of patients identified with pathogenic variants in genes other than BRCA1/2 from 2007 through 2017 to determine if radiographic surveillance was in accordance with NCCN guidelines for mammography and consideration of magnetic resonance imaging (MRI). Exclusions included variants of unknown significance, pathogenic variants not associated with an increased risk of breast cancer, and previous breast cancer diagnosis.
Results
After exclusions, 35 patients with pathogenic variants in ATM, CDH1, CHEK2, NBN, PALB2, PTEN, and STK11 genes were reviewed to assess whether radiographic surveillance was in accordance with NCCN guidelines. Guidelines for those with variants in ATM, CHEK2 and NBN includes annual mammography with tomosynthesis and consideration of breast MRI at age 40, variants in CDH1 and PALB2 at age 30, variants in PTEN at age 30–35 or 5–10 years before the earliest family breast cancer, and variants in STK11 at age 25. Of these 35 patients, 11 (31%) received mammography only; 11 (31%) received mammography and MRI, and 13 (37%) received no radiographic surveillance. Two of the 35 (6%) patients who received radiographic surveillance were diagnosed with ductal carcinoma in situ or invasive breast cancer.
Conclusion
Thirty-one percent of patients with pathogenic variants in genes other than BRCA1/2 received both mammography and MRI. Thirty-seven percent of patients with these highly penetrant and moderately penetrant genes received no radiographic follow-up, clearly demonstrating an opportunity for improvement.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. https://doi.org/10.1038/nature11412.
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291-1299. https://doi.org/10.1093/annonc/mdv022. Epub 2015 Jan 20.
Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol. 2011;12(5):477–488. https://doi.org/10.1016/s1470-2045(11)70076-6.
Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 pathogenic variants and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol. 2015;22:3282–3288. https://doi.org/10.1245/s10434-015-4754-2.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/familial high-risk assessment: breast and ovarian. Version 2.2019. www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016;13:581-588. https://doi.org/10.1038/nrclinonc.2016.90.
Schneider K, Zelley K, Nichols KE, et al. Li-Fraumeni Syndrome. 1999 [Updated 2013 Apr 11]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2013. http://www.ncbi.nlm.nih.gov/books/NBK1311/ (Accessed on September 5, 2013).
Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz–eghers syndrome. Nature. 1998;391:184–187.
Beggs AD, Latchford AR, Vasen HF, et al. Peutz–eghers syndrome: a systematic review and recommendations for management. Gut. 2010;59:975–986. https://doi.org/10.1136/gut.2009.198499.
Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1:23–32. https://doi.org/10.1001/jamaoncol.2014.168.
Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400–407. https://doi.org/10.1158/1078-0432.ccr-11-2283.
Chenevix-Trench G, Spurdle AB, Gatei M, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002;94:205–215.
Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the copenhagen general population study. J Clin Oncol. 2016;34:12081216. https://doi.org/10.1200/jco.2015.63.3594.
Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453–460. https://doi.org/10.1200/jco.18.01631.
Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721–1730. https://doi.org/10.1002/cncr.30498.
Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst. 2018;110(7):714–725. https://doi.org/10.1093/jnci/djx265.
American Society of Breast Surgeons Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. Published February 2019.
Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43(13):1905–1917. Epub 2007 Aug 2. Review. PubMed PMID: 17681781.
Petelin L, Trainer AH, Mitchell G, Liew D, James PA. Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. Genet Med. 2018;20(10):1145–1156. https://doi.org/10.1038/gim.2017.255. Epub 2018 Jan 11. PubMed PMID: 29323669.
Acknowledgement
We thank Geraldine M Chadwick, AuD, who provided medical writing support on behalf of the Department of Surgery, Carolinas Medical Center.
Funding
This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hudson, L., Gower, N., Lenarcic, S. et al. Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants. Ann Surg Oncol 27, 2248–2254 (2020). https://doi.org/10.1245/s10434-019-08191-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-019-08191-0